Optavia's meal-replacement system produces modest short-term weight loss with substantial regain after stopping; GLP-1 medications produce roughly 2-3x the average weight loss and address the underlying appetite biology that diet-only approaches don't touch.
Luma Health's semaglutide ($197/month) and tirzepatide ($297/month) work through a different mechanism than meal replacement — and the two aren't mutually exclusive.
Optavia and GLP-1 medications represent fundamentally different theories of weight loss: one relies on structured caloric restriction through prepackaged meals, the other alters the biology of hunger and satiety directly. Here's how the evidence actually compares.
How Each Approach Works
Optavia's core program (the 5&1 Plan) uses very-low-calorie meal replacements, typically 800-1,200 calories per day, paired with one-on-one coaching. GLP-1 medications like semaglutide and tirzepatide work by mimicking gut hormones that regulate appetite, slow gastric emptying, and improve insulin sensitivity — addressing the biological drivers of hunger rather than relying on external caloric restriction alone.
What the Data Shows
Optavia reports average weight loss of about 12 pounds over 12 weeks on its most popular plan. Broader research on meal-replacement programs like Optavia shows average short-term weight loss of 5-8% of body weight, with substantial regain — commonly 80-95% of lost weight returning within 2-5 years after stopping. In contrast, the STEP 1 trial showed semaglutide producing 14.9% average weight loss over 68 weeks, and SURMOUNT-1 showed tirzepatide producing over 20% average weight loss over 72 weeks, with the SELECT trial additionally showing a reduction in major cardiovascular events — a benefit no diet-only program has demonstrated in comparable trial data.
Why Regain Patterns Differ
Very-low-calorie diets don't address the physiological mechanisms driving hunger and weight regain — elevated ghrelin, reduced leptin, and metabolic adaptation remain largely unchanged once normal eating resumes. GLP-1 medications directly target these appetite-regulating pathways, which is part of why their effect persists as long as the medication is continued, and why stopping either approach tends to lead to some regain, through different mechanisms.
Optavia itself has built a GLP-1 support offering, recognizing that structured nutrition can complement medication rather than compete with it. Adequate protein intake and portion structure matter on a GLP-1, particularly since medication-driven weight loss can include meaningful lean-mass reduction if protein intake isn't prioritized. A structured meal system paired with GLP-1 treatment isn't contradictory — it's a reasonable combination for patients who want both.
Cost Comparison
Optavia's core program costs vary by meal plan and coaching tier, with its dedicated GLP-1 support offering starting around $386.50/month plus separate medication cost through its LifeMD partnership (which offers its own $99/month subscription tier for the medical visit). Luma Health's compounded semaglutide is $197/month and tirzepatide is $297/month, flat, without a separate meal-replacement product cost layered on top.
Which Approach Fits You
- Want a structured, coach-guided meal system without medication
- Prefer prepackaged meals to reduce decision fatigue
- Have more modest weight-loss goals
- Want to address the biological drivers of appetite directly
- Have significant weight to lose and want stronger average results
- Are interested in the additional cardiovascular benefit data
Address the biology,
not just the calories
Compounded semaglutide at $197/month or tirzepatide at $297/month — medical evaluation, provider visits, and shipping all included.
Get Started → Or start your free health assessmentFrequently Asked Questions
Not in terms of average weight loss magnitude. Optavia reports roughly 12 pounds over 12 weeks, while GLP-1 clinical trials show 14.9-20%+ body-weight reduction over 68-72 weeks — a meaningfully larger effect.
Research on similar very-low-calorie meal-replacement programs shows substantial regain, commonly 80-95% of lost weight returning within 2-5 years after stopping.
Yes, Optavia has built specific GLP-1 support products recognizing this combination. Structured nutrition can complement medication, particularly around protein intake to help preserve muscle mass.
The SELECT trial showed semaglutide reduced major adverse cardiovascular events in patients with obesity but without diabetes — a benefit not demonstrated in comparable diet-only program trial data.
Optavia's GLP-1 program provides coaching and nutrition support alongside a LifeMD medical connection for prescribing; the program fee is separate from and additional to the medication cost itself.
It depends on the specific plans compared. A flat-rate compounded GLP-1 provider without a meal-replacement product can be more cost-effective than Optavia's combined coaching-plus-medication program.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PubMed 37952131
- Sargeant JA, et al. A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. Endocrinol Metab (Seoul). 2019. PubMed 31261506